Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D. Cook N, et al. Among authors: nebozhyn m. Br J Cancer. 2018 Mar 20;118(6):793-801. doi: 10.1038/bjc.2017.495. Epub 2018 Feb 13. Br J Cancer. 2018. PMID: 29438372 Free PMC article. Clinical Trial.
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ. Sclafani F, et al. Among authors: nebozhyn m. Int J Cancer. 2017 Jan 15;140(2):431-439. doi: 10.1002/ijc.30453. Epub 2016 Oct 17. Int J Cancer. 2017. PMID: 27681944 Free article. Clinical Trial.
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ. Sclafani F, et al. Among authors: nebozhyn m. J Natl Cancer Inst. 2015 Sep 23;107(12):djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec. J Natl Cancer Inst. 2015. PMID: 26405092 Clinical Trial.
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B, Mauro D. Anderson PM, et al. Among authors: nebozhyn m. Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. doi: 10.1002/pbc.26087. Epub 2016 Jun 30. Pediatr Blood Cancer. 2016. PMID: 27362300 Free PMC article. Clinical Trial.
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC. Galanis E, et al. Among authors: nebozhyn m. Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161. Neuro Oncol. 2018. PMID: 29016887 Free PMC article. Clinical Trial.
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.
Cristescu R, Nebozhyn M, Zhang C, Albright A, Kobie J, Huang L, Zhao Q, Wang A, Ma H, Alexander Cao Z, Morrissey M, Ribas A, Grivas P, Cescon DW, McClanahan TK, Snyder A, Ayers M, Lunceford J, Loboda A. Cristescu R, et al. Among authors: nebozhyn m. Clin Cancer Res. 2022 Apr 14;28(8):1680-1689. doi: 10.1158/1078-0432.CCR-21-3329. Clin Cancer Res. 2022. PMID: 34965943 Free PMC article.
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.
Georgiev P, Muise ES, Linn DE, Hinton MC, Wang Y, Cai M, Cadzow L, Wilson DC, Sukumar S, Caniga M, Chen L, Xiao H, Yearley JH, Sriram V, Nebozhyn M, Sathe M, Blumenschein WM, Kerr KS, Hirsch HA, Javaid S, Olow AK, Moy LY, Chiang DY, Loboda A, Cristescu R, Sadekova S, Long BJ, McClanahan TK, Pinheiro EM. Georgiev P, et al. Among authors: nebozhyn m. Mol Cancer Ther. 2022 Mar 1;21(3):427-439. doi: 10.1158/1535-7163.MCT-21-0561. Mol Cancer Ther. 2022. PMID: 34965960 Free PMC article.
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.
Shitara K, Di Bartolomeo M, Mandala M, Ryu MH, Caglevic C, Olesinski T, Chung HC, Muro K, Goekkurt E, McDermott RS, Mansoor W, Wainberg ZA, Shih CS, Kobie J, Nebozhyn M, Cristescu R, Cao ZA, Loboda A, Özgüroğlu M. Shitara K, et al. Among authors: nebozhyn m. J Immunother Cancer. 2023 Jun;11(6):e006920. doi: 10.1136/jitc-2023-006920. J Immunother Cancer. 2023. PMID: 37399357 Free PMC article. Clinical Trial.
Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma.
Xiang H, Pan Y, Sze MA, Wlodarska M, Li L, van de Mark KA, Qamar H, Moure CJ, Linn DE, Hai J, Huo Y, Clarke J, Tan TG, Ho S, Teng KW, Ramli MN, Nebozhyn M, Zhang C, Barlow J, Gustafson CE, Gornisiewicz S, Albertson TP, Korle SL, Bueno R, Moy LY, Vollmann EH, Chiang DY, Brandish PE, Loboda A. Xiang H, et al. Among authors: nebozhyn m. Cancer Res. 2024 May 2;84(9):1410-1425. doi: 10.1158/0008-5472.CAN-23-1183. Cancer Res. 2024. PMID: 38335304 Free PMC article.
40 results